viewTissue Regenix Group PLC

Tissue Regenix adds sales specialist for US orthopaedic drive

Distin is a specialist in building sales through targeted marketing and has worked for a number of other US companies.

Knee cartilages are expected to be approved by end of 2016

Tissue Regenix (LON:TRX)  has strengthened the management of its US operation with the appointment of Drew Distin to its new orthopaedic subsidiary.

Distin is a specialist in building sales through targeted marketing and has worked for a number of other US companies.

His remit is to plan the launch Tissue Regenix’s new range of orthopaedic products on the US.

Clinical trials are currently ongoing in Europe for OrthoPure XM (porcine meniscus) and OrthoPure XT (porcine tendon) products, with the a target a CE mark for the XM knee cartilage by the end of 2016.

In the US, Tissue will initially focus on  human tissue applications, initially starting with the human tendon (OrthoPure HT).

Tissue Regenix is currently in partnership with tissue bank Community Tissue Services (CTS) for the manufacturing of its wound care product DermaPure.

Peter Hamer, Tissue Regenix Orthopaedic’s commercial director, said Distin brings a wealth of experience.

“This is a very exciting time for Orthopaedics at Tissue Regenix as we continue enrolment of our OrthoPure XT clinical trial and await submission for the CE mark with OrthoPure XM.

“We are on course to complete these tasks within the timeline predicted."

Quick facts: Tissue Regenix Group PLC

Price: 0.485 GBX

Market: AIM
Market Cap: £34.11 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...


Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

2 min read